Statement Of Cash Flows [Abstract]

GenSight Biologics S.A. - Filing #5982864

Concept 2024-01-01 to
2024-12-31
As at
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operating activities
12 937 EUR
24,663,000 EUR
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities
1,000 EUR
10,000 EUR
Purchase of intangible assets, classified as investing activities
0 EUR
0 EUR
Cash flows from (used in) investing activities
17,000 EUR
209,000 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
13 997 EUR
3 957 EUR
Proceeds from borrowings, classified as financing activities
0 EUR
14,182,000 EUR
Repayments of borrowings, classified as financing activities
2 153 EUR
0 EUR
Payments of lease liabilities, classified as financing activities
742,000 EUR
792,000 EUR
Interest paid, classified as financing activities
278,000 EUR
368,000 EUR
Cash flows from (used in) financing activities
13 542 EUR
15,859,000 EUR
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
623,000 EUR
8,595,000 EUR
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
293,000 EUR
119,000 EUR
Cash and cash equivalents
2 464 EUR
2,134,000 EUR
10,610,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.